Hypertension as a mask of ANCA-associated glomerulonephritis
V. S. Bashnyak,
E. M. Mamutova,
S. A. Berns,
I. I. Almazova,
N. V. Shashkova,
R. N. Shepel,
O. M. Drapkina https://doi.org/10.18705/1607-419X-2022-28-1-96-102
Abstract
Glomerulonephritis associated with antineutrophil cytoplasmic antibodies (ANCA) is one of the causes of renal parenchymal disease, which can lead to secondary hypertension (HTN). Clinical course of HTN in this case is usually mild, however, high blood pressure can become the only reason to refer to a primary care physician. We report a case of a 45-year old woman with renal parenchymal disease due to ANCA-glomerulonephritis and secondary HTN. HTN was the only clinical manifestation of the disease led to the hospital admission. With this clinical case we emphasize that primary care physicians should always attempt to identify secondary causes of HTN.
About the Authors
V. S. Bashnyak
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Vladislav S. Bashnyak, MD, Cardiologist, Laboratory Assistant, Laboratory of Pathogenetic aspects of Comorbidity, Postgraduate Student
10 b. 3, Petroverigsky lane, Moscow, 101000
E. M. Mamutova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Elvira M. Mamutova, MD, Internist, Laboratory Assistant, Laboratory for the Study of Intestinal Microbiota
Moscow
S. A. Berns
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Svetlana A. Berns, MD, PhD, DSc, Professor, Head, Laboratory of Pathogenetic Aspects of Comorbidity
Moscow
I. I. Almazova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Ilda I. Almazova, MD, PhD, Associate Professor, Department of Therapy and General Medical Practice
Moscow
N. V. Shashkova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Nadezhda V. Shashkova, MD, PhD, Head, Department of Emergency Cardiology
Moscow
R. N. Shepel
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Ruslan N. Shepel, MD, PhD, Deputy Director for the Longterm Development of Medical Activities
Moscow
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Oksana M. Drapkina, MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Chief freelance Specialist in Therapy and General Medical Practice of the Ministry of Health of the Russian Federation, Honored Doctor of the Russian Federation, Director, National Medical Research Center for Therapy and Preventive Medicine
Moscow
References
1. National clinical guidelines “Arterial hypertension in adults”. Russian Society of Cardiology. 2020. In Russian.
2. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–1254. doi:10.1093/eurheartj/eht534
3. Kronbichler A, Leierer J, Gauckler P, Shin JI. Comorbidities in ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59(Suppl 3):79–83. doi:10.1093/rheumatology/kez617
4. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
5. Draft clinical guidelines “Kidney damage in ANCAassociated vasculitis (ANCA-associated glomerulonephritis)”. Association of Nephrologists of Russia. 2021. In Russian.
6. Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond). 2017;17(1):60–64. doi:10.7861/clinmedicine.17–1–60
7. Beketova TV, Kokosadze NV. Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the phenomenon of IgG4 overproduction. Literature review and own observations. Rheumatol Sci Pract. 2020;58(5):550–559. doi: 10.47360/1995-4484-2020-550-559. In Russian.
8. Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol. 2002;13(7):1953–1960. doi:10.1097/01.asn.0000016442.33680.3e
9. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–498.
10. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–494.
11. Tziomalos K. Secondary hypertension: novel insights. Curr Hypertens Rev. 2020;16(1):11. doi:10.2174/1573402115666190416161116
12. Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D. ANCA-associated vasculitis: an update. J Clin Med. 2021;10(7):1446. doi:10.3390/jcm10071446
13. Kozlovskaya NL, Gordovskaya NB, Korotchaeva Yu V. National guidelines “Diagnosis and treatment of ANCA-associated glomerulonephritis (kidney damage in ANCA-associated vasculitis)”. 2014. In Russian.
14. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594.
15. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al. 2012 revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi:10.1002/art.37715
Review
For citations:
Bashnyak V.S., Mamutova E.M., Berns S.A., Almazova I.I., Shashkova N.V., Shepel R.N., Drapkina O.M. Hypertension as a mask of ANCA-associated glomerulonephritis. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2022;28(1):96-102. (In Russ.) https://doi.org/10.18705/1607-419X-2022-28-1-96-102
Views:
866
Email this article 